Clinical trials: Nephrocalcinosis
Nephrocalcinosis
Diagnostic Work-up of Nephrocalcinosis in Children
This cross-sectional study aims to identify the underlying etiology of nephrocalcinosis and to evaluate the diagnostic work-up in infants and children presenting to Assiut University Children's Hospital.
- Trial name
- NCT07882355
- Volunteers
- 40 people
- Sponsor
- Assiut University
Nephrocalcinosis
Epidemiology and Risk Factors of Nephrolithiasis and Nephrocalcinosis With Pediatric Onset
The aim of the study is to build a database of pediatric patients affected by nephrolithiasis or nephrocalcinosis in order to investigate their clinical and epidemiological characteristics.
- Trial name
- Calcolosi-kid (NCT07874087)
- Where
- Italy
- Volunteers
- 800 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Idiopathic Infantile Hypercalcaemia - Severe Form, Genetic Disease
Rifampin in CYP24A1-related Hypercalcemia and Hypercalciuria
This study evaluates the efficacy of rifampin in the treatment of hypercalcemia and/or hypercalciuria in participants with at least one inactivating mutation of the CYP24A1 gene.
- Conditions
- Idiopathic Infantile Hypercalcaemia - Severe Form, Genetic Disease, Hypercalcemia, Idiopathic, of Infancy, Hypercalciuric Hypercalcemia
- Trial name
- RICHH (NCT03301038)
- Testing
- Rifampin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Children's Hospital of Philadelphia
Paraffinoma, Granuloma, Foreign-Body
The GranStone Trial
This study will investigate whether treatment with empagliflozin or losartan can reduce the risk of kidney stone formation in patients with paraffin disease, a condition caused by the injection of paraffin oil into muscle tissue…
- Trial name
- NCT07828002
- Testing
- empagliflozin (Jardiance) 25 mg, Losartan 100 mg
- Where
- Denmark
- Volunteers
- 100 people
- Sponsor
- Martin Blomberg Jensen
Autosomal Dominant Hypocalcemia (ADH)
Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1
The primary purpose of the study is to understand the effectiveness, safety, and tolerability of encaleret when compared to standard of care (SoC) treatment in participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1).
- Trial name
- CALIBRATE (NCT05680818)
- Testing
- Encaleret, Standard of Care
- Where
- 25 sites in United States, Australia and 8 more
- Volunteers
- 67 people
- Sponsor
- Calcilytix Therapeutics, Inc., a BridgeBio company
X-linked Hypophosphatemia (XLH)
Effective Dosing of Burosumab in XLH
X-linked hypophosphataemia (XLH) is a rare, hereditary condition. The genetic defect leads to low blood phosphate levels and vitamin D suppression. Phosphate is required for strong bones and teeth and to store energy in cells.
- Trial name
- NCT07183579
- Where
- United Kingdom
- Volunteers
- 120 people
- Sponsor
- University of Nottingham
Autosomal Dominant Hypocalcemia
ADH1 and ADH2 Disease Monitoring Study (DMS)
A global, multi-center, Disease Monitoring Study (DMS) in participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1) or Autosomal Dominant Hypocalcemia Type 2 (ADH2) designed to characterize ADH1 and ADH2 disease…
- Trial name
- CLARIFY (NCT05227287)
- Where
- 27 sites in United States, Australia and 11 more
- Volunteers
- 95 people
- Sponsor
- Calcilytix Therapeutics, Inc., a BridgeBio company
Urologic Diseases, Urinary Tract Infections
Effect of Comprehensive Spa Care on Kidney and Urological Conditions: A Clinical Study in Adult Patients
This is a single-arm, pretest-posttest study evaluating the effects of a 21-day comprehensive spa care (Komplexní lázeňská léčebně rehabilitační péče, KLP) on patients with nephrological and urological conditions treated at a spa…
- Conditions
- Urologic Diseases, Urinary Tract Infections, Nephrolithiasis, Nephrocalcinosis
- Trial name
- Uro-Nefro (NCT07435844)
- Testing
- Comprehensive Spa Care, Exercise Therapy, Dietotherapy
- Where
- Czechia
- Volunteers
- 150 people
- Sponsor
- Institute of Spa and Balneology, public research institution
Enamel Renal Syndrome
Renal and Vascular Phenotypic Characterization of Patients With Enamel Renal Syndrome Due to a Pathogenic Variant of the FAM20A Gene and Pathophysiological Study of Ectopic Calcifications
In the research, the investigators will characterize the renal and vascular damage and look for factors favoring the formation of calcification induced by enamel renal syndrome.
- Trial name
- FAM-Cal (NCT07285421)
- Testing
- urinary proteome, urinary metabolome, Evaluation of plasma mineralization factors
- Where
- 2 sites in France
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Nephrolithiasis
Is CYP24A1 Heterozygosity a Risk Factor for Nephrolithiasis?
Biallelic loss-of-function variants in CYP24A1 have been identified as a common genetic cause of autosomal recessive hypercalcemia (ARH, ORPHA 300547, 1 in 80,000 live births), characterized by low PTH (parathyroid hormone)…
- Trial name
- HETEROCYP (NCT07201701)
- Testing
- Supplementary blood samples for PBMC analysis at V2
- Where
- 2 sites in France
- Volunteers
- 45 people
- Sponsor
- Hospices Civils de Lyon
Nephrocalcinosis, Renal Calculi
Randall's Plaque Study: Pathogenesis and Relationship to Nephrolithiasis
Kidney stones are very common. They affect 3-5% of the population in the United States. Many people are hospitalized for the treatment of kidney stones and some may die.
- Conditions
- Nephrocalcinosis, Renal Calculi, Hypercalciuria, Hyperparathyroidism
- Trial name
- NCT00169806
- Testing
- videotape for mapping of renal anatomy and papillary biopsy
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Indiana Kidney Stone Institute
Primary Hyperoxaluria Type 3
Natural History of Patients With PH3 and a History of Stone Events
This is a natural history study of adults, adolescents, and children (starting at birth) with genetically confirmed primary hyperoxaluria type 3 (PH3) who have a history of stone events during the last 3 years and/or the presence…
- Trial name
- PHYOX-OBX (NCT04542590)
- Where
- 6 sites in United States, Canada and 3 more
- Volunteers
- 7 people
- Sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Nephrolithiasis, Nephrocalcinosis
Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Fluconazole in Hypercalcicuric Patients With Increased 1.25(OH) 2D Levels
Hypercalciuria is one of the most frequent metabolic disorders associated with nephrolithiasis and/or nephrocalcinosis leading to Chronic Kidney Disease (CKD) and bone complications in adults.
- Conditions
- Nephrolithiasis, Nephrocalcinosis, Hypercalciuria
- Trial name
- FLUCOLITH (NCT04495608)
- Testing
- Fluconazole
- Where
- 11 sites in France
- Volunteers
- 56 people
- Sponsor
- Hospices Civils de Lyon
Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis
National Registry of Rare Kidney Diseases
The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research.
- Conditions
- Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis, AHL Amyloidosis, AL Amyloidosis
- Trial name
- RaDaR (NCT06065852)
- Where
- United Kingdom
- Volunteers
- 35,000 people
- Sponsor
- UK Kidney Association
Nephrocalcinosis
Prevalence and Risk Factors of Nephrocalcinosis in Children at Sohag University Hospital
To study prevalence, risk factors, possible etiologies, clinical presentation and outcome of nephrocalcinosis in children at Sohag University Hospital.
- Trial name
- NCT05862207
- Volunteers
- 50 people
- Sponsor
- Sohag University
Nephrocalcinosis, Preterm Infant
The Incidence and the Risk Factors of Nephrocalcinosis in Very Preterm Infants
The study aims to assess the incidence and the risk factors of nephrocalcinosis in very preterm infants using patient data collected during hospitalisation at the Neonatology Centre.
- Trial name
- NCT04382976
- Where
- Lithuania
- Volunteers
- 171 people
- Sponsor
- Vilnius University
Primary Hyperoxaluria
Phenotyping of Primary Hyperoxaluria
985 / 5000 Résultats de traduction Primary hyperoxaluria is a rare autosomal recessive disease with an estimated prevalence of around 1 to 3 cases per million population.
- Trial name
- PHENO-HOPLA (NCT05107830)
- Where
- France
- Volunteers
- 186 people
- Sponsor
- University Hospital, Strasbourg, France
Idiopathic Infantile Hypercalcemia - Mild Form
The Antibiotic Rifampin to Reduce High Levels of Blood and Urine Calcium in IIH
Idiopathic infantile hypercalcemia(IIH) is a rare,genetic disorder of mineral metabolism. Biallelic loss of functions mutations of CYP24A1, the gene encoding the 24-hydroxylase enzyme that represents the principal pathway for…
- Trial name
- NCT03384121
- Testing
- Rifampin 150 mg, 300 mg capsules and 25 mg/mL oral suspension
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- The Hospital for Sick Children
Prematurity, Nephrocalcinosis
Preterm Infants and Nephrocalcinosis
Nephrocalcinosis (NC), defined as calcification of renal tissue, has been reported to occur in 7-41% of premature infants. Causes of NC are likely multi-factorial, and infants born prematurely and with very low birth weight…
- Conditions
- Prematurity, Nephrocalcinosis, Hypercalciuria
- Trial name
- NC (NCT02438267)
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- University of Utah
Primary Hyperoxaluria, Nephrocalcinosis
International Registry for Primary Hyperoxaluria
The purpose of this study is to collect medical information from a large number of patients in many areas of the world with primary hyperoxaluria.
- Conditions
- Primary Hyperoxaluria, Nephrocalcinosis, Kidney Stones
- Trial name
- NCT00875823
- Where
- 4 sites in United States
- Sponsor
- Mayo Clinic